Papers

• Comparative effectiveness and cost-effectiveness analysis of a urine metabolomics test vs. alternative colorectal cancer screening strategies
  S Barichello, L Deng, K Ismond, D Loomes, EK Kirwin, H Wang, D Chang, LW Svenson, NX Thanh
  International Journal of Colorectal Disease, November 1. 2019, 0179-1958

• Urinary Metabolomics to Identifty a Unique Biomarker Panel for Detecting Colorectal Cancer: A Multicenter Study
  L Deng, K Ismond, Z Liu, J Constable, H Wang, OI Alatise, MR Weiser, TP Kingham, D Chang
  Cancer Epidemiology, Biomarkers & Prevention, August, 2019, 10.1158/1055-9965.EPI-18-1291

• Development and Validation of a High-Throughput Mass Spectometry Based Urine Metabolomic Test for the Detection of Colonic Adenomatous Polyps
  L Deng, D Chang, RR Foshaug, R Eisner, VK Tso, DS Wishart, RN Fedorak
  Metabolites, June 22, 2017, 7(3), 32 

• Clinical validation of a novel urine-based metabolomic test for the detection of colonic polyps on Chinese population
  L Deng, H Fang, V Tso, Y Sun, RR Foshaug, SC Krahn, F Zhang, Y Yan, H Xu, D Chang, Y Zhang, RN Fedorak
  International Journal of Colorectal Disease:Available Online, 2016 Dec 01

• Consistency of Metabolite Determination from NMR Spectra over Time and Between Operators
  V Tso, R Eisner, S Macleod, KP Ismond, RR Foshaug, H Wang, R Joseph, D Chang, N Taylor, RN Fedorak
  Metabolomics: Open Access, 2015 Sept; 5(3):151

• Budgeted transcript discovery: a framework for joint exploration and validation studies
  S Khan, R Greiner
  Bioinformatics and Biomedicine, 2014 IEEE International Conference Nov;188-91

• Urine-based test for detection of colonic polyps: the coming of age
  H Wang, R Eisner, RN Fedorak
  Colorectal Cancer, 2014 Jun;3(3):239-41
  
  
• Development and validation of a highly sensitive urine-based test to identify patients with colonic adenomatous polyps
  H Wang, V Tso, C Wong, D Sadowski, RN Fedorak
  Clinical and Translational Gastroenterology, 2014 Mar;5:e54
  
  
• A machine-learned predictor of colonic polyps based on urinary metabolomics
  R Eisner, R Greiner, V Tso, H Wang, RN Fedorak
  Biomed Research International 2013 Nov;2013:303982
  
  
• Metabolomic profiles are gender, disease and time specific in the interleukin-10 gene-deficient mouse model of inflammatory bowel disease
  VK Tso, BC Sydora, RR Foshaug, TA Churchill, J Doyle, CM Slupsky, RN Fedorak
  PLoS ONE,2013 Jul;8(7):e67654
  
  
• Patients undergoing colorectal cancer screening underestimate their cancer risk and delay presentation for screening
  H Wang, N Gies, C Wong, D Sadowski, B Moysey, RN Fedorak
  Canadian Journal of Gastroenterology, 2012 Jul;26(7):419-23
  
  
• The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer
  CK Wong, RN Fedorak, CI Prosser, ME Stewart, S Veldhuyzen van Zanten, DC Sadowski
  International Journal of Colorectal Disease, 2012 Dec;27(12):1657-64
  
  
• Metabolomics and detection of colorectal cancer in humans - a systematic review
  H Wang, V Tso, C Slupsky, RN Fedorak
  Future Oncology, 2010 Sep;6(9):1395-1406

Conferences

• Loomes DE, Nguyen TX, Kirwin E, Wang H, Svenson L, Fedorak R. A novel urine-based metabolomics screening test for adenomatous polyps is superior to a colonoscopy-based strategy. Digestive Disease Week, Washington, DC. May 16-19, 2015. Gastroenterology, 148(4, Supplement 1):S-744.
  
  
• Dykstra M, Switzer N, Eisner R, Tso V, Foshaug RR, Fedorak RN, Wang H. Urine-based metabolomic diagnostic tests predict response to chemotherapy and adverse events in patients with colorectal cancer (Sa1917). Digestive Disease Week, Washington, DC. May 16-19, 2015. Gastroenterology, 148(4, Supplement 1):S-354.
  
  
• Dykstra M, Switzer N, Eisner R, Ismond KP, Fedorak R, Wang H. Can urine metabolomics predict a patient's tolerance to chemotherapy in colorectal cancer? Canadian Digestive Diseases Week, Banff, AB. February 27-March 2, 2015. 29(Supplement SA):A102.
  
  
• Khan S, Greiner R. Budgeted transcript discovery: a framework for joint exploration and validation studies. IEEE International Conference on Bioinformatics and Biomedicine (BIBM), Belfast, Ireland. November 2-5, 2014. pgs. 188-191.
  
  
• Khan S, Greiner R. The budgeted biomarker discovery problem: a variant of association studies. AAAI Workshops, Quebec City, QC. June 18, 2014. pgs. 17-20.
  
  
• Keshteli A, van den Brand FE, Wishart D, Mandal R, Bjorndahl TC, Beomsoo H, Baarda J, Kroeker KI, Valcheva R, Fedorak R, Madsen K, Dieleman LA. Dietary fat intake, fecal calprotectin and metabolomic profiles predict relapse of ulcerative colitis (Su1302). Digestive Disease Week, Chicago, IL. May 3-6, 2014. 146(5, Supplement 1):S-430.
  
  
• Kao D, Hotte N, Tso V, Madsen K, Fedorak R. Nuclear magnetic resonance (NMR)-based urine metabolomic analysis of patients with Clostridium difficile infection (Tu1763). Digestive Disease Week, Chicago, IL. May 3-6, 2014. 146(5, Supplement 1):S-837.
  
  
• Wong K, Foshaug RR, Tso V, Bressler B, Devlin S, Kroeker KI, Dieleman LA, Fedorak RN. NMR urine metabolomics in the prediction of response to infliximab in patients with UC and CD. Digestive Disease Week, Orlando, FL. May 18-21, 2013. Gastroenterology, 144(5, Supplement 1):S-780.
  
  
• Tso R, Gillevet PM, Greiner R, Dieleman LA, Rioux KP, Kaplan GG, Barkema H, Koleva P, Valcheva R, Kuenzig E, Kroeker KI, Fedorak RN, Madsen K. Distinctive urinary metabolite profiles correlate with microbial composition and are linked with endoscopic post-operative disease recurrence in Crohn's disease patients. Digestive Disease Week, Orlando, FL. May 18-21, 2013. Gastroenterology, 144(5, Supplement 1):S-193.
  
  
• Wang H, Gies N, Tso V, Foshaug RR, Fedorak RN. The highly accurate urine metabolomics diagnostic test for colonic adenoma reverts to normal following adenoma removal (Tu1196). Digestive Disease Week, San Diego, CA. May 19-22, 2012. Gastroenterology, 142(5, Supplement 1):S-771.
  
  
• Wong CK, Fedorak RN, Prosser CI, van Zanten SV, Sadowski DC. Enhanced detection of screening relevant colorectal neoplasias with fecal immunochemical (FIT): diagnostic performance relative to guaiac based tests and colonoscopy (Su1128). Digestive Disease Week, Chicago, IL. May 7-10, 2011. Gastroenterology, 140(5, Supplement 1):S-585.
  
  
• Wong CK, Fedorak RN, Prosser CI, van Zanten SV, Sadowski DC. Efficacy of a single day fecal immunochemical occult blood testing (FIT) collection strategy for screening relevant colorectal neoplasias (Su1122). Digestive Disease Week, Chicago, IL. May 7-10, 2011. Gastroenterology, 140(5, Supplement 1):S-584.
  
  
• Wang H, Schiller DE, Tso V, Slupsky C, Wong CK, Fedorak RN. A new and highly sensitive screening tool for colorectal adenomatous polyps using a spot urine metabolomics test. Digestive Disease Week, Chicago, IL. May 7-10, 2011. Gastroenterology, 140(5, Supplement 1):S-420.
  
  
• Wang H, Schiller DE, Slupsky C, Wong CK, Tso V, Fedorak RN. NMR urine metabolomics detect colorectal adenomatous polyps with high sensitivity. Canadian Digestive Diseases Week, Vancouver, BC. February 26-March 1, 2011. Canadian Journal of Gastroenterology, 25(Supplement A):A009.
  
  
• Tso V. Nuclear magnetic resonance (NMR) analysis of urine establishes metabolomic fingerprints that distinguish IBD from non-IBD and the bacterial small molecules present at the initiation of disease (206). Digestive Disease Week, New Orleans, LA. May 1-5, 2010. Gastroenterology, 138(5, Supplement 1):S-38.
  
  
• Tso V. Nuclear magnetic resonance (NMR) analysis of urine establishes metabolomic fingerprints that distinguish IBD from non-IBD and the bacterial small molecules present at the initiation of disease Canadian Digestive Diseases Week, Toronto, ON. February 27-March 2, 2010. Canadian Journal of Gastroenterology, 24(Supplement SA):A237.
  
  
• Tso V. Nuclear magnetic resonance (NMR) analysis of urine establishes metabolomic fingerprints that distinguish IBD from non-IBD and the bacterial small molecules present at the initiation of disease (P2A-079). Metabolomics2010, Amsterdam, The Netherlands. June 27-July 1, 2010. pg. 125.
  
  
• Tso V, Sydora B, Foshaug RR, Slupsky C, Fedorak R. Nuclear magnetic resonance (NMR) spectrometry metabolomic urine fingerprint separates IBD from non-IBD. Canadian Digestive Diseases Week, Banff, AB. February 27-March 2, 2009. Canadian Journal of Gastroenterology, 23(Supplement SA):115A.
  
  
• Siffledeen JS, Rankin KN, Fu H, Dieleman LA, Slupsky C, Fedorak R. Metabolomics in inflammatory bowel disease: differentiating patients with or without IBD. Digestive Disease Week, San Diego, CA. May 17-22, 2008. Gastroenterology, 134(4):A-203.
  
  
• Siffledeen JS, Fu H, Slupsky C, Fedorak RN. Urinary metabolomic profiles differ between patients with and without inflammatory bowel disease. Canadian Digestive Diseases Week, Montreal, QC. February 29-March 3, 2008. Canadian Journal of Gastroenterology, 22(Supplement SA):102A.
  
  
• Murdoch TB, Fu H, Martin S, Slupsky C, Fedorak RN. Metabolomic analysis of inflammatory bowel disease in interleukin-10 gene-deficient mice. Digestive Disease Week, Washington, DC. May 19-24, 2007. Gastroenterology, 132(4, Supplement 1):A-362.